Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Pre-Meal protein drink may tame blood sugar spikes

NCT ID NCT07174323

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether taking Nextida-GC (a collagen peptide) or whey protein before breakfast can lower blood sugar spikes after eating. Thirty-two healthy adults, some with prediabetes, drank the supplement 30 minutes before, 10 minutes before, or with a standard breakfast. Researchers measured blood sugar and insulin levels over three hours to find the best timing.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

32 people

The number who actually took part.

Started

Sep 2025

Finished

Dec 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Non-pregnant, non-lactating. * BMI 18.5 to 35.0 kg/m² inclusive. * n=20 with prediabetes: fasting glucose 5.6-6.9 mmol/L and/or HbA1c 5.7-6.4%. * n=12 without prediabetes: fasting glucose \<5.6 mmol/L and HbA1c \<5.7%. * Systolic blood pressure \<160mmHg and diastolic blood pressure \<100mmHg. * Willing to abstain from unusual strenuous exercise and consuming alcoholic drinks for 24 hours before study days. * Willing to refrain from smoking tobacco or using marijuana in any form (including but not limited to smoking, vaping, edibles, tinctures, or other ingestible or inhalable preparations) for 12h before and during study visits. * Willing to consume study products that contain animal derived ingredients * Understand the study procedures and willing to provide informed consent to participate in the study and authorization to release relevant protected health information to the study investigator. * Eligible to receive income in Canada and covered by a health insurance plan such as OHIP. Exclusion Criteria: * Failure to meet any one of the inclusion criteria. * Major trauma or surgical event within 3 months of screening. * Use of supplements containing collagen and/or high dose of chromium (\>500mcg). * The presence of any laboratory result, health condition, illness or drug use that increases risk to the subject or to others or may affect the results, as judged by the Qualified Investigator. * Unwillingness or inability to comply with experimental procedures and to follow INQUIS safety guidelines. * Known intolerance, sensitivity, or allergy to any ingredients in the study test meals. * Subject is currently participating or recently (within 30 days of screening) participated in a clinical trial involving long-term exposure (greater than 24 hours) to an investigational drug, nutritional supplement, or lifestyle modification

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Normal plasma glucose are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Insulin Resistance prediabetes syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • INQUIS Clinical Research

    Toronto, Ontario, M5C2N8, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.